PURPOSE: Limited information is available on the impact of chemotherapy (CTX)-induced neurotoxicity on adult survivors' symptom experience and quality of life (QOL). Purposes were to describe occurrence of hearing loss and tinnitus and evaluate for differences in phenotypic characteristics and measures of sensation, balance, perceived stress, symptom burden, and QOL between survivors who received neurotoxic CTX and did (i.e., neurotoxicity group) and did not (i.e., no neurotoxicity group) develop neurotoxicity. Neurotoxicity was defined as the presence of chemotherapy-induced neuropathy (CIN), hearing loss, and tinnitus. Survivors in the no neurotoxicity group had none of these conditions. METHODS: Survivors (n = 609) completed questionnaires that evaluated hearing loss, tinnitus, stress, symptoms, and QOL. Objective measures of sensation and balance were evaluated. RESULTS: Of the 609 survivors evaluated, 68.6% did and 31.4% did not have CIN. Of the survivors without CIN, 42.4% reported either hearing loss and/or tinnitus and 48.1% of the survivors with CIN reported some form of ototoxicity. Compared to the no neurotoxicity group (n = 110), survivors in the neurotoxicity group (n = 85) were older, were less likely to be employed, had a higher comorbidity burden, and a higher symptom burden, higher levels of perceived stress, and poorer QOL (all p < .05). CONCLUSIONS: Findings suggest that CIN, hearing loss, and tinnitus are relatively common conditions in survivors who received neurotoxic CTX. IMPLICATIONS FOR CANCER SURVIVORS: Survivors need to be evaluated for these neurotoxicities and receive appropriate interventions. Referrals to audiologists and physical therapists are warranted to improve survivors' hearing ability, functional status, and QOL.
PURPOSE: Limited information is available on the impact of chemotherapy (CTX)-induced neurotoxicity on adult survivors' symptom experience and quality of life (QOL). Purposes were to describe occurrence of hearing loss and tinnitus and evaluate for differences in phenotypic characteristics and measures of sensation, balance, perceived stress, symptom burden, and QOL between survivors who received neurotoxic CTX and did (i.e., neurotoxicity group) and did not (i.e., no neurotoxicity group) develop neurotoxicity. Neurotoxicity was defined as the presence of chemotherapy-induced neuropathy (CIN), hearing loss, and tinnitus. Survivors in the no neurotoxicity group had none of these conditions. METHODS: Survivors (n = 609) completed questionnaires that evaluated hearing loss, tinnitus, stress, symptoms, and QOL. Objective measures of sensation and balance were evaluated. RESULTS: Of the 609 survivors evaluated, 68.6% did and 31.4% did not have CIN. Of the survivors without CIN, 42.4% reported either hearing loss and/or tinnitus and 48.1% of the survivors with CIN reported some form of ototoxicity. Compared to the no neurotoxicity group (n = 110), survivors in the neurotoxicity group (n = 85) were older, were less likely to be employed, had a higher comorbidity burden, and a higher symptom burden, higher levels of perceived stress, and poorer QOL (all p < .05). CONCLUSIONS: Findings suggest that CIN, hearing loss, and tinnitus are relatively common conditions in survivors who received neurotoxic CTX. IMPLICATIONS FOR CANCER SURVIVORS: Survivors need to be evaluated for these neurotoxicities and receive appropriate interventions. Referrals to audiologists and physical therapists are warranted to improve survivors' hearing ability, functional status, and QOL.
Authors: Penelope R Brock; Kristin R Knight; David R Freyer; Kathleen C M Campbell; Peter S Steyger; Brian W Blakley; Shahrad R Rassekh; Kay W Chang; Brian J Fligor; Kaukab Rajput; Michael Sullivan; Edward A Neuwelt Journal: J Clin Oncol Date: 2012-04-30 Impact factor: 44.544
Authors: Brandi T Cuevas; Daniel C Hughes; Dorothy Long Parma; Rose A Treviño-Whitaker; Sagar Ghosh; Rong Li; Amelie G Ramirez Journal: Support Care Cancer Date: 2013-11-19 Impact factor: 3.603
Authors: Alexandre Chan; Daniel L Hertz; Manuel Morales; Elizabeth J Adams; Sharon Gordon; Chia Jie Tan; Nathan P Staff; Jayesh Kamath; Jeong Oh; Shivani Shinde; Doreen Pon; Niharkia Dixit; James D'Olimpio; Cristina Dumitrescu; Margherita Gobbo; Kord Kober; Samantha Mayo; Linda Pang; Ishwaria Subbiah; Andreas S Beutler; Katherine B Peters; Charles Loprinzi; Maryam B Lustberg Journal: Support Care Cancer Date: 2019-07-30 Impact factor: 3.603
Authors: Kord M Kober; Melissa Mazor; Gary Abrams; Adam Olshen; Yvette P Conley; Marilyn Hammer; Mark Schumacher; Margaret Chesney; Betty Smoot; Judy Mastick; Steven M Paul; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2018-08-30 Impact factor: 3.612
Authors: Christine Miaskowski; Steven M Paul; Judy Mastick; Mark Schumacher; Yvette P Conley; Betty Smoot; Gary Abrams; Kord M Kober; Steven Cheung; Jennifer Henderson-Sabes; Margaret Chesney; Melissa Mazor; Margaret Wallhagen; Jon D Levine Journal: Eur J Oncol Nurs Date: 2017-11-07 Impact factor: 2.398
Authors: Jaini J Paltian; Angélica S Dos Reis; Amanda W S Martins; Eduardo B Blödorn; Eduardo N Dellagostin; Liane K Soares; Ricardo F Schumacher; Vinícius F Campos; Diego Alves; Cristiane Luchese; Ethel Antunes Wilhelm Journal: Mol Neurobiol Date: 2022-08-15 Impact factor: 5.682
Authors: Martial Caillaud; Danielle Thompson; Wisam Toma; Alyssa White; Jared Mann; Jane L Roberts; John W Bigbee; David A Gewirtz; M Imad Damaj Journal: Pharmaceutics Date: 2022-06-17 Impact factor: 6.525
Authors: Melissa Mazor; Steven M Paul; Margaret A Chesney; Lee-May Chen; Betty Smoot; Kimberly Topp; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Cancer Date: 2019-09-10 Impact factor: 6.860
Authors: K Y Ho; Katherine K W Lam; W Xia; J O K Chung; Ankie T Cheung; Laurie L K Ho; S Y Chiu; Godfrey C F Chan; William H C Li Journal: Health Qual Life Outcomes Date: 2021-07-06 Impact factor: 3.186